Larazotide
Also known as: AT-1001, larazotide acetate
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
An orally-acting peptide that regulates intestinal tight junctions, studied primarily as an adjunct in celiac disease.
What it is & how it works
What it is
Larazotide (AT-1001) is an orally-acting peptide that works on intestinal tight junctions — the seals between gut-lining cells that regulate what crosses the barrier.
How it is thought to work
It is designed to tighten those junctions, reducing barrier permeability. In celiac disease this was studied as a way to blunt the response to inadvertent gluten exposure.
The evidence and the caveat
It has genuine late-stage human trial data — better than most gut peptides — but results were mixed and it isn’t approved. The broader “leaky gut” framing reaches well past what’s proven.
What it's discussed & studied for
- Intestinal barrier / 'leaky gut' discussion
- Celiac disease (clinical trials)
Discussion of a use is not a claim that it works or is approved.
Research status
Reached late-stage human trials for celiac disease; results have been mixed and it is not approved. Other gut-barrier uses are extrapolated.
Evidence quality
Among the better-studied gut peptides, with real human trial data — but it has not cleared approval, and broader 'leaky gut' claims outrun the evidence.
Dosing discussion
Doses were defined in clinical trials for celiac disease; there is no approved label or validated consumer protocol.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Acts locally in the gut and was generally well tolerated in trials, but it is unapproved and long-term consumer use is not validated.
Sourcing literacy
No approved product; research-market material is unverified.
Selected literature
FAQ
Is larazotide approved?
No. It reached late-stage celiac disease trials with mixed results and is not approved.